Infliximab as a first-line therapy in newly diagnosed Crohn’s Disease ( CD ) promotes long-term sustained remission and alters the course of the disease / C., B., DE ANGELIS, G.L., O., B., B., B., F., F., F., V., M., C., S., C.. - In: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. - ISSN 0277-2116. - 40:(2005), pp. 645-646. (J Pediatr Gastroenterol Nutr ).
Infliximab as a first-line therapy in newly diagnosed Crohn’s Disease ( CD ) promotes long-term sustained remission and alters the course of the disease
DE ANGELIS, Gian Luigi;
2005-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
